Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol. Issue 8 (5th August 2021)

• Record Type: Journal Article
• Authors: Mendelsohn, Simon C; Mulenga, Humphrey; Mbandi, Stanley Kimbung; Darboe, Fatoumatta; Shelton, Mary; Scriba, Thomas J; Hatherill, Mark
• Is Part Of: BMJ open. Volume 11:Issue 8(2021)
• Publication Date: 2021-08-05
• Subjects: tuberculosis -- HIV & AIDS -- molecular diagnostics; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-048623
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Current tuberculosis triage and predictive tools offer poor accuracy and are ineffective for detecting asymptomatic disease in people living with HIV (PLHIV). Host tuberculosis transcriptomic biomarkers hold promise for diagnosing prevalent and predicting progression to incident tuberculosis and guiding further investigation, preventive therapy and follow-up. We aim to conduct a systematic review of performance of transcriptomic signatures of tuberculosis in PLHIV. Methods and analysis: We will search MEDLINE (PubMed), WOS Core Collection, Biological Abstracts, and SciELO Citation Index (Web of Science), Africa-Wide Information and General Science Abstracts (EBSCOhost), Scopus, and Cochrane Central Register of Controlled Trials databases for articles published in English between 1990 and 2020. Case–control, cross-sectional, cohort and randomised controlled studies evaluating performance of diagnostic and prognostic host-response transcriptomic signatures in PLHIV of all ages and settings will be included. Eligible studies will include PLHIV in signature test or validation cohorts, and use microbiological, clinical, or composite reference standards for pulmonary or extrapulmonary tuberculosis diagnosis. Study quality will be evaluated using the 'Quality Assessment of Diagnostic Accuracy Studies-2' tool and cumulative review evidence assessed using the 'Grading of Recommendations Assessment, Development and Evaluation' approach. Study selection, quality appraisal and data extraction will be performed independently by two reviewers. Study, cohort and signature characteristics of included studies will be tabulated, and a narrative synthesis of findings presented. Primary outcomes of interest, biomarker sensitivity and specificity with estimate precision, will be summarised in forest plots. Expected heterogeneity in signature characteristics, study settings, and study designs precludes meta-analysis and pooling of results. Review reporting will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy Studies guidelines. Ethics and dissemination: Formal ethics approval is not required as primary human participant data will not be collected. Results will be disseminated through peer-reviewed publication and conference presentation. PROSPERO registration number: CRD42021224155.